105 related articles for article (PubMed ID: 28424416)
1. Loss of thyroid hormone receptor interactor 13 inhibits cell proliferation and survival in human chronic lymphocytic leukemia.
Zhou K; Zhang W; Zhang Q; Gui R; Zhao H; Chai X; Li Y; Wei X; Song Y
Oncotarget; 2017 Apr; 8(15):25469-25481. PubMed ID: 28424416
[TBL] [Abstract][Full Text] [Related]
2. USF2 promotes autophagy and proliferation in chronic lymphocytic leukemia by inhibiting STUB1-induced NFAT5 ubiquitination.
Chen B; Zhao Y; Xu S; Jiang F; Nie Y; Tang A; Zhou Q
Ann Hematol; 2024 Feb; 103(2):533-544. PubMed ID: 37950051
[TBL] [Abstract][Full Text] [Related]
3. Targeting TRIP13 for overcoming anticancer drug resistance (Review).
Zhao L; Ye S; Jing S; Gao YJ; He T
Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37800638
[TBL] [Abstract][Full Text] [Related]
4. The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13-MAPK-YWHAE signaling pathway.
Wang Y; Dong S; Hu K; Xu L; Feng Q; Li B; Wang G; Chen G; Zhang B; Jia X; Xu Z; Gao X; Zhang H; Xie Y; Lu M; Chang S; Song D; Wu X; Jia Q; Zhu H; Zhou J; Zhu W; Shi J
J Transl Med; 2023 Nov; 21(1):858. PubMed ID: 38012658
[TBL] [Abstract][Full Text] [Related]
5. AKAP12 and IGFBP4 Are Prognostic Factors for Chronic Lymphocytic Leukemia.
Shi Y; Xu X; He Z; Tao H; Chen Y; Zhang L; Tao S; Ding B; Wang C; Yu L
Acta Haematol; 2023; 146(6):473-480. PubMed ID: 37605556
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as a therapeutic strategy in CLL.
Largeot A; Klapp V; Viry E; Gonder S; Fernandez Botana I; Blomme A; Benzarti M; Pierson S; Duculty C; Marttila P; Wierz M; Gargiulo E; Pagano G; An N; El Hachem N; Perez Hernandez D; Chakraborty S; Ysebaert L; François JH; Cortez Clemente S; Berchem G; Efremov DG; Dittmar G; Szpakowska M; Chevigné A; Nazarov PV; Helleday T; Close P; Meiser J; Stamatopoulos B; Désaubry L; Paggetti J; Moussay E
Blood; 2023 Jun; 141(26):3166-3183. PubMed ID: 37084385
[TBL] [Abstract][Full Text] [Related]
7. Growth and survival of B-chronic lymphocytic leukaemia cells.
Söderberg O
Med Oncol; 1998 Jul; 15(2):73-8. PubMed ID: 9789213
[TBL] [Abstract][Full Text] [Related]
8. Clinical heterogeneity reflects biologic diversity in chronic lymphocytic leukemia.
Moore JS; Friedman DF; Silberstein LE; Besa EC; Nowell PC
Crit Rev Oncol Hematol; 1995 Aug; 20(1-2):141-64. PubMed ID: 7576195
[TBL] [Abstract][Full Text] [Related]
9. TI17, a novel compound, exerts anti-MM activity by impairing Trip13 function of DSBs repair and enhancing DNA damage.
Chang S; Xiao W; Xie Y; Xu Z; Li B; Wang G; Hu K; Zhang Y; Zhou J; Song D; Zhu H; Wu X; Lu Y; Shi J; Zhu W
Cancer Med; 2023 Dec; 12(23):21321-21334. PubMed ID: 37942576
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivo.
Dong S; Hu K; Shi Y; Wang G; Yu D; Zhao Y; Zhang H; Wang Y; Sun H; Xu Z; Jia Q; Li Y; Li Y; Li B; Shi J; Zhu W
Bioorg Med Chem Lett; 2024 Jan; 98():129590. PubMed ID: 38092072
[TBL] [Abstract][Full Text] [Related]
11. An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer.
Dhasmana S; Dhasmana A; Rios S; Enriquez-Perez IA; Khan S; Afaq F; Haque S; Manne U; Yallapu MM; Chauhan SC
Comput Struct Biotechnol J; 2023; 21():5765-5775. PubMed ID: 38074464
[TBL] [Abstract][Full Text] [Related]
12. Chronic lymphocytic leukaemia genomics and the precision medicine era.
Ghamlouch H; Nguyen-Khac F; Bernard OA
Br J Haematol; 2017 Sep; 178(6):852-870. PubMed ID: 28444740
[TBL] [Abstract][Full Text] [Related]
13. Rethinking the usefulness of bone marrow biopsy on treatment decision in CLL patients at diagnosis.
Eren R; Doğu MH; Emir S; Huq GE; Okçu O; Altındal Ş; Yokuş O; Suyanı E
Ann Hematol; 2017 Aug; 96(8):1315-1321. PubMed ID: 28435987
[TBL] [Abstract][Full Text] [Related]
14. TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer.
Sheng N; Yan L; Wu K; You W; Gong J; Hu L; Tan G; Chen H; Wang Z
Cell Death Dis; 2018 Mar; 9(3):402. PubMed ID: 29540729
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia.
Putowski M; Podgórniak M; Piróg M; Knap J; Zaleska J; Purkot J; Zawiślak J; Zakrzewska E; Karczmarczyk A; Własiuk P; Subocz E; Giannopoulos K
Pol Arch Intern Med; 2017 Apr; 127(4):238-244. PubMed ID: 28424451
[TBL] [Abstract][Full Text] [Related]
16. Mad2 Overexpression Uncovers a Critical Role for TRIP13 in Mitotic Exit.
Marks DH; Thomas R; Chin Y; Shah R; Khoo C; Benezra R
Cell Rep; 2017 May; 19(9):1832-1845. PubMed ID: 28564602
[TBL] [Abstract][Full Text] [Related]
17. Biallelic TRIP13 mutations predispose to Wilms tumor and chromosome missegregation.
Yost S; de Wolf B; Hanks S; Zachariou A; Marcozzi C; Clarke M; de Voer R; Etemad B; Uijttewaal E; Ramsay E; Wylie H; Elliott A; Picton S; Smith A; Smithson S; Seal S; Ruark E; Houge G; Pines J; Kops GJPL; Rahman N
Nat Genet; 2017 Jul; 49(7):1148-1151. PubMed ID: 28553959
[TBL] [Abstract][Full Text] [Related]
18. IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia.
Piccaluga PP; Agostinelli C; Righi S; Ciccone M; Re MC; Musumeci G; Diani E; Signoretto C; Bon I; Piccin O; Cuneo A; Tripodo C; Ponti C; Zipeto D; Landolfo S; Gibellini D
APMIS; 2017 Jun; 125(6):511-522. PubMed ID: 28517553
[TBL] [Abstract][Full Text] [Related]
19. NF-κB p50 (
Chen TL; Tran M; Lakshmanan A; Harrington BK; Gupta N; Goettl VM; Lehman AM; Trudeau S; Lucas DM; Johnson AJ; Byrd JC; Hertlein E
Blood; 2017 Jul; 130(3):376-379. PubMed ID: 28515090
[No Abstract] [Full Text] [Related]
20. The oncogenic role of TRIP13 in regulating proliferation, invasion, and cell cycle checkpoint in NSCLC cells.
Zhang Q; Dong Y; Hao S; Tong Y; Luo Q; Aerxiding P
Int J Clin Exp Pathol; 2019; 12(9):3357-3366. PubMed ID: 31934178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
